Edmonton, Canada

Zahra Shire

This inventor holds 1 USPTO granted patent. Top assignee: University of Alberta. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zahra Shire. Retrieved from https://idiyas.com/inventor/zahra-shire

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zahra Shire: Innovator in Imidopiperidine Compounds

Introduction

Zahra Shire is a prominent inventor based in Edmonton, Canada. She has made significant contributions to the field of biochemistry, particularly through her innovative work on imidopiperidine compounds.

Latest Patents

Zahra holds a patent for "Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase." This patent describes the development of imidopiperidine compounds that serve as inhibitors for human polynucleotide kinase phosphatase, showcasing her expertise in medicinal chemistry.

Career Highlights

Zahra is affiliated with the University of Alberta, where she conducts her research and contributes to the academic community. Her work has garnered attention for its potential applications in therapeutic settings.

Collaborations

Zahra has collaborated with notable colleagues, including Dennis Hall and Michael Weinfeld, enhancing the impact of her research through teamwork and shared expertise.

Conclusion

Zahra Shire is a trailblazer in her field, with a focus on innovative compounds that could lead to significant advancements in medicine. Her contributions reflect her dedication to scientific progress and collaboration.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…